Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …

Exploitation of the protein degradation machinery as a therapeutic strategy to degrade
oncogenic proteins is experiencing revolutionary advances with the development of …

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for
targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly …

Proteolysis-targeting chimeric molecules (PROTACs), which attract much more attention
today, may be a potential way to treat cancer. PROTACs are made up of ligands of target …

Proteolysis-targeting chimeras (PROTACs) have shown great therapeutic potential by
degrading various disease-causing proteins, particularly those related to tumors. Therefore …

Abstract PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules
consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” to …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Curing malignant carcinomas is a grand ambition in the development of human health. Over
the past decades, targeted therapies have become one of the most successful ways of …

Abstract The PROteolysis Targeting Chimeras (PROTACs) approach has attracted extensive
attention in the past decade, which represents an emerging therapeutic modality with the …

Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically,
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …